TY  - JOUR
AU  - Fuchs, Juri
AU  - Murtha-Lemekhova, Anastasia
AU  - Pfeiffenberger, Jan
AU  - Fichtner, Alexander
AU  - Günther, Patrick
AU  - Halama, Niels
AU  - Mayer, Philipp
AU  - Hornuss, Daniel
AU  - Klotz, Rosa
AU  - Probst, Pascal
AU  - Hoffmann, Katrin
TI  - Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta-analyses.
JO  - Systematic Reviews
VL  - 11
IS  - 1
SN  - 2046-4053
CY  - London
PB  - Biomed Central
M1  - DKFZ-2022-02648
SP  - 235
PY  - 2022
N1  - Commentary
AB  - Rare liver lesions and diseases have seldomly aroused major interest of researchers. For most guidelines, presumably similar clinical conditions are pooled without detailed investigations of singularities that they present.A multidisciplinary project aiming to establish evidence-based therapies for rare liver diseases has been founded. A series of systematic reviews and meta-analyses will be the starting point for a structured development of guidelines for rare conditions of the liver affecting pediatric and adult populations. The novel approach will be focusing on case reports and small patient series with distinct rare liver diseases without pooling several presumably acceptably similar conditions. Thus, a vital resource of information will be utilized, which has been largely neglected hitherto.Highly specific recommendations based on highest available evidence will therefore be developed for specific conditions, advancing the individualized medicine approach for the afflicted patients.
KW  - Evidence-based medicine (Other)
KW  - Meta-analysis (Other)
KW  - RELIVE (Other)
KW  - Rare liver disease (Other)
KW  - Rare liver tumors (Other)
KW  - Systematic reviews (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36329524
DO  - DOI:10.1186/s13643-022-02105-0
UR  - https://inrepo02.dkfz.de/record/182439
ER  -